Table 1.
Participant characteristics (n = 12).
| Age (y), mean ± SD (range) | 17.8 ± 2.1 (16–21) |
|---|---|
| Weight (kg), mean ± SD (range) | 78 ± 29 (47–148) |
| BMI, mean ± SD (range) | 29 ± 10 (18.4–52.8) |
| BMI z-score, mean ± SD (range) | 1.2 ± 1.2 (−1.3 to 2.8) |
| Gender identity, n (%) | |
| Female, cisgender | 11 (92%) |
| Other (self-described)* | 1 (8%) |
| Self-described race and ethnicity, n (%) | |
| Asian | 1 (8%) |
| White | 7 (58%) |
| More than one race | 3 (25%) |
| Unknown/not reported | 1 (8%) |
| Hispanic | 5 (42%) |
| Substance use, n (%) | |
| Nicotine, daily | 2 (17%) |
| Alcohol, regularly* | 4 (33%) |
| Marijuana, regularly* | 1 (8.3%) |
| Concurrent medications n (%)^ | |
| SSRI/SNRI | 8 (67%) |
| Atypical antipsychotic | 2 (17%) |
| Hormonal contraceptives | 3 (25%) |
| Psychiatric diagnoses, n (%) | |
| Anorexia nervosa, binge-purge | 9 (75%) |
| Bulimia nervosa | 1 (8.3%) |
| Binge eating disorder | 2 (17%) |
| Major depressive disorder | 10 (83%) |
| Anxiety disorders | 11 (92%) |
| PTSD | 3 (25%) |
| Bipolar | 1 (8.3%) |
| ADHD | 3 (25%) |
| Autism spectrum | 1 (8.3%) |
*
Regularly defined as weekly or monthly use. No one reported daily alcohol or marijuana use.
^Medications taken by only 1 participant each: stimulant, alpha agonist and gabapentin.
ADHD, attentive deficit hyperactivity disorder; BMI, body mass index; kg, kilogram; PTSD, post-traumatic stress disorder; SD, standard deviation; SNRI, serotonin norepinephrine reuptake inhibitors; SSRI, selective serotonin reuptake inhibitors; y, years.